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Abstract
Autism Spectrum Disorders (ASD) is a spectrum of highly heritable neurodevelopmental disorders in which known
mutations contribute to disease risk in 20% of cases. Here, we report the results of the largest blood transcriptome study to
date that aims to identify differences in 170 ASD cases and 115 age/sex-matched controls and to evaluate the utility of gene
expression profiling as a tool to aid in the diagnosis of ASD. The differentially expressed genes were enriched for the
neurotrophin signaling, long-term potentiation/depression, and notch signaling pathways. We developed a 55-gene
prediction model, using a cross-validation strategy, on a sample cohort of 66 male ASD cases and 33 age-matched male
controls (P1). Subsequently, 104 ASD cases and 82 controls were recruited and used as a validation set (P2). This 55-gene
expression signature achieved 68% classification accuracy with the validation cohort (area under the receiver operating
characteristic curve (AUC): 0.70 [95% confidence interval [CI]: 0.62–0.77]). Not surprisingly, our prediction model that was
built and trained with male samples performed well for males (AUC 0.73, 95% CI 0.65–0.82), but not for female samples (AUC
0.51, 95% CI 0.36–0.67). The 55-gene signature also performed robustly when the prediction model was trained with P2
male samples to classify P1 samples (AUC 0.69, 95% CI 0.58–0.80). Our result suggests that the use of blood expression
profiling for ASD detection may be feasible. Further study is required to determine the age at which such a test should be
deployed, and what genetic characteristics of ASD can be identified.
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Introduction
Autism Spectrum Disorders (ASD) cover a broad spectrum of
developmental delays in social interaction, verbal and non-verbal
communication, and restricted repetitive patterns of behavior and
interests with onset before 3 years of age. ASDs include autistic
disorder, pervasive developmental disorder-not otherwise specified
and Asperger’s Disorder as sub classified in the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-
IV-TR) [1]. The prevalence of ASD has been reportedly
increasing in recent decades, with a current estimation at 1 in
88 [2]. There are long waiting lists for evaluation at most centers
with expertise and, despite the progress made in adopting
instruments such as the Autism Diagnostic Interview-Revised
(ADI-R) and the Autism Diagnostic Observation Schedule
(ADOS), there remains significant debate regarding the prognostic
value and accuracy of existing instruments [3,4]. Additionally, the
Centers for Disease Control have identified addressing the delay in
diagnosis of ASD (median age at diagnosis is currently 5.7 years) as
a public health priority [5,6]. Moreover, early diagnosis and
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e49475behavioral intervention improve outcomes [7], highlighting a
continued need and interest in diagnostic tests or biomarkers that
can be used in primary pediatric care to reduce the time to
accurate diagnosis.
The high heritability of ASD, with 60–90% concordance
between identical twins vs. 0–10% in fraternal twins [8,9], has led
to the hope that a collection of DNA mutations can be used
diagnostically for ASD. Indeed, a range of mutations, from single
nucleotide changes to copy number variants (hundreds to millions
of bases affected) to karyotypically visible anomalies, have been
catalogued in patients with ASD. However, individually most of
these mutations account for less than 1% of autism cases and
collectively they account for less than 20% [8]. Chromosomal
microarray analysis (CMA), which detects 7–10% of children
diagnosed with ASD [10–12], has been recommended as a first-
tier genetic test for patients who may have ASD. Although DNA
sequence and chromosomal variants may provide mechanistic
insight, CMA characterizes genomic variants in only a minority of
children with ASD.
Gene expression microarrays enable the measurement of
messenger RNA for most of the thousands of known genes.
Specifically, they measure which part of the DNA in the genome is
transcribed for cellular function at a given time. Multivariate gene
expression–based prediction models developed from cases and
non-cases have been widely used for diagnosis, screening,
prediction of treatment response, and prognosis [13,14]. RNA
expression, across hundreds of genes in peripheral blood, has also
been shown to be perturbed in patients with ASD relative to
controls using gene expression microarrays [15–23]. How these
RNA expression differences translate into classification accuracy is
not yet known. Nonetheless, as RNA expression is controlled by
both the DNA code from which it is transcribed and the
physiological and environmental milieu, these early results are
encouraging. We performed the largest blood gene expression
study to date of ASD, designed specifically to provide insight into
the performance of a blood expression signature that classifies
children with ASD from controls, particularly after an increased
index of suspicion based on parent and/or pediatric assessment.
Validation of this signature utilized an additional cohort for
assessment of classification accuracy.
Results
ASD patients were recruited from the Developmental Medicine
Center, the Division of Genetics, and the Department of
Neurology at Children’s Hospital Boston (CHB) with additional
samples obtained from Boston Medical Center, Cambridge Health
Alliance, Tufts Medical Center, and Mass General Hospital in
collaboration with the Autism Consortium of Boston. Study
inclusion criteria consisted of a clinical diagnosis of ASD by DSM-
IV-TR criteria and an age.24 months. Patients with ASD
recruited for this study have undergone diagnostic assessment,
using ADOS and ADI-R, as well as comprehensive clinical testing
such as cognitive testing, language measures, medical history,
height and weight, head circumference, and behavioral question-
naires. Two independently collected data sets (hereafter P1 and
P2) consisted of 99 (66 ASDs and 33 controls) and 186 (104 ASDs
and 82 controls) individuals, respectively. The patients with known
syndromic disorders such as fragile X syndrome, tuberous
sclerosis, Landau-Kleffner syndrome, and Klinefelter syndrome
were not included in this study.
A total of 115 controls were enrolled concurrently. Collection of
control samples was performed through partnerships with both the
Division of Endocrinology of Boston Children’s Hospital (12
individuals from the P1 cohort) and Children’s Hospital Primary
Care Center (CHPCC) (21 individuals from P1, and all 82
individuals from P2). Patients enrolled from the outpatient
endocrine clinic were healthy children with idiopathic short
stature, including genetic short stature and constitutional delay of
growth, and were having clinical blood draws. We followed up on
the clinical blood draw results to confirm they had no abnormal
findings and those that did were withdrawn from the study.
Patients seen in the CHPCC for a well-child visit that involved a
routine blood draw (for example, to obtain lead levels) were
offered enrollment. A diagnosis of a chronic disease, intellectual
disability, ASD, or other neurological disorder acted as exclusion
criteria from our control group. Complete phenotypic information
is available with microarray data (Gene Expression Omnibus
identifier GSE18123). Each cohort’s clinical and demographic
information is shown in Table 1.
Written consent was obtained from the parent or guardian of all
children participating in the study, and was approved by the
Institutional Review Boards (IRB) of each participating institution.
Approval for the study as a whole was also obtained from the
Boston Children’s Hospital IRB.
Table 1. Characteristics of patients with autism spectrum
disorders and controls in the training set (P1) and in the
validation set (P2).
Training Set (P1) Validation Set (P2)
Characteristic ASD Control ASD Control
No. 66 33 104 82
Age - years
Mean 8.0 9.0 8.4 8.1
Interquartile range 5.5–9.7 4.0–13.1 5.0–11.0 4.1–12.3
Male - no. (%) 66 (100) 33 (100) 80 (77) 48 (59)
Diagnosis (Male %)
Autistic Disorder 31 - 40 (75) -
PDD, NOS 26 - 49 (76) -
Asperger’s Disorder 9 - 15 (87) -
Race - no.
Caucasian 60 13 96 33
Black 0 5 0 8
Asian 1 1 3 2
Mixed 5 1 4 8
Other - 4 - 21
Unknown 1 9 1 10
Ethnicity
Hispanic - no. 2 9 8 36
Unknown - no. 1 - - -
Developmental delay - no. 21 5 51 3
Learning Disorder – no. 9 - -
Psychiatric Disorder - no. 14 4 32 1
Neurological Disorder - no. 8 - 18 -
Gastrointestinal Disorder - no. 24 - 20 -
Autoimmune Disorder - no. - - 7 -
Cerebral Palsy - no. - - 1 -
doi:10.1371/journal.pone.0049475.t001
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and controls in the P1 (Welch’s t-test P=0.29) or P2 cohort
(P=0.73). Ages of ASD samples between the P1 and P2
populations were also not different (P=0.52). Thirteen of 66
patients with ASD in P1 and 42 out of 104 in P2 were evaluated
for verbal and non-verbal IQ. There was no significant difference
in average IQs between P1 and P2 (verbal IQ P=0.872, non-
verbal IQ P=0.624, and total IQ P=0.929). One ASD patient in
P1 met the criteria of mild intellectual disability (verbal IQ=69,
non-verbal IQ=65, and total IQ=67), and 5 males and 2 females
of P2 met the criteria of moderate to profound intellectual
disability.
The disease incidence in ASD is discordant between males and
females, with males 4 times more likely to develop disease.
Additionally, our preliminary analysis revealed higher heteroge-
neity in RNA levels in females with ASD than in males, possibly
due to the smaller number of females included in this study or to
the sexual dimorphism in the expression of the disorder [17].
Considering these factors, only males were included in the P1
cohort (both ASD and control samples), which was used to build a
prediction model for ASD. We subsequently tested the perfor-
mance of the predictive model in both males and females in the P2
cohort (although the number of female controls was higher than
that of female ASD—Fisher’s exact test P=0.01 in P2).
Blood gene expression changes in ASD
Due to the time-span covered by this study, expression studies
were performed by microarray profiling using an earlier version of
the Affymetrix array (U133p2) for the P1 data set and a later
version (GeneST) for the P2 data set. After selecting the best
matching probesets between the two platforms (see Methods),
principal component analysis was performed to project samples
into the first two principal components. P1 and P2 samples did not
form two clusters after combining the two datasets, which were
centered and scaled independently (Fig. S1) [13].
There were 489 and 610 transcripts differentially expressed
between ASD cases and controls in the P1 and P2 datasets,
respectively (Welch’s t-test P,0.001, corresponding FDRs 0.029
(P1), and 0.023 (P2)) (Tables S1 and S2). Of these, 23 genes—
ARID4B, ARMCX3, C10orf28, CTBP2, DDX3Y, JRKL, MTERFD3,
NFYA, NGEF, PNN, RLF, RNF145, TIGD1, TUBB2A, UTY, YES1,
ZNF117, ZNF322, ZNF445, ZNF514, ZNF518B, ZNF540, and
ZNF763—were significant in both cohorts. To calculate the
significance of this overlap, we shuffled sample labels in both data
sets 200,000 times and counted the number of permutations with
as many or more overlapping genes. Out of 200,000 permutations,
only 2 had at least 23 overlapping genes between the two data sets,
yielding a permutation P=10
25. The overlap of 23 genes also
showed a significant trend using the hypergeometric distribution
(P=0.0721) [24]. In the P2 dataset, 352 genes were significant for
male patients compared to male controls while 48 genes were
significant for female groups (Welch’s t-test P,0.001, correspond-
ing FDRs 0.028 (P2 males) and 0.60 (P2 females)). One gene –
POLR3H – was differentially expressed in both males and females.
Twelve of the 489 differentially expressed genes in the P1
dataset were selected for validation by quantitative RT-PCR. The
12 genes selected had an average fold change between ASD and
controls greater than 1.5 and a mean expression level on the array
greater than 150. These were CREBZF, HNRNPA2B1, KIDINS220,
LBR, MED23, RBBP6, SPATA13, SULF2, TMEM30A, ZDHHC17,
ZMAT1, and ZNF12. Eleven of 12 genes (all except ZMAT1) were
successfully validated using qRT-PCR (Table 2).
Out of 489 differentially expressed genes in P1, 10 genes (AFF2,
CD44, CNTNAP3, CREBBP, DAPK1, JMJD1C, NIPBL, PTPRC,
SH3KBP1, and STK39) were found in the expert-curated ASD
candidate-genes database (https://gene.sfari.org/) [25]. Addition-
ally, 44 genes mapped to reported copy number variation regions
(http://projects.tcag.ca/autism/) (Table 3) [12]. Interestingly, rare
mutations in or CNVs containing JMJD1C [26], PTPRC [27], and
SH3KBP1 [28] have been reported in a small numbers of cases.
For example, STK39 was identified as an ASD candidate gene
from linkage analysis of 334 families [29]. Two genes—CD44 and
DAPK1—were differentially expressed between 5 monozygotic
twins pairs who were discordant for clinical severity [30]. AFF2,
DOCK8, NIPBL, and RPS6KA3 were implicated in intellectual
disability. AFF2 encodes FRAXE-associated mental retardation
protein (FMR2) within which small changes were found in patients
with intellectual disability and developmental delay [31], and
significantly more frequent rare variants were detected in AFF2 by
massively parallel sequencing of males with ASD [32]. Heterozy-
gous changes in the DOCK8 gene have been previously reported in
two unrelated patients, one by deletion testing and one by a
translocation breakpoint; these disruptions are associated with
intellectual disability and developmental disability (MRD2, MIM
ID# 614113) [33]. Mutations in NIPBL result in Cornelia de
Lange syndrome (MIM ID# 122470), a disorder characterized by
dysmorphic facial features, growth delay, limb reduction defects as
well as intellectual disability [34]. Among the differentially
expressed genes in the P2 dataset, only ATRX was associated with
intellectual disability according to the Online Mendelian Inher-
itance in Man (OMIM) database [35].
When each diagnostic subtype was compared to controls in the
P1 dataset, 178, 56, and 3 genes were significant for autistic
disorder (AUT), pervasive developmental disorder-not otherwise
specified (PDDNOS), and Asperger’s disorder (ASP), respectively
(One-way analysis of variance (ANOVA) with Dunnett’s post hoc
test P,0.001, corresponding FDRs 0.076 (AUT), 0.24
(PDDNOS), and 1.0 (ASP)). Among the significant genes in
ASP, only one gene, PTPRE, overlapped with the AUT vs. control
or PDDNOS vs. control comparisons while 36 genes were in
common between AUT vs. control and PDDNOS vs. control (Fig.
S2).
Four of 66 ASD cases in the P1 dataset had mild intellectual
disability. When we compared the 4 ASD cases with mild
intellectual disability to the 62 ASD cases without intellectual
disability, we found 70 differentially expressed genes (P,0.001,
corresponding FDR 0.12), of which none has yet been implicated
in the intellectual disability process as reported in the OMIM and
Human Gene Mutation Databases [36]. The relation between
ASD and intellectual disability needs to be further explored in the
context of the genetic background that they share.
Expression profiling also identified chromosomal abnormalities.
For instance, we identified an affected male that had high
expression of the X-inactive-specific transcript (XIST); the
expression values were comparable to those of females. Subse-
quent karyotyping confirmed Klinefelter syndrome in this
individual, and the case was excluded in this study for further
analysis.
Perturbed biological pathways and identification of
heterogeneous subgroups
We used a modified Fisher’s exact test (i.e., Expression Analysis
Systematic Explorer [EASE] score) to see what biological
pathways were enriched with the differentially expressed genes
in P1 using the DAVID functional annotation system [37,38]. This
metric allowed us to calculate which processes were overrepre-
sented in the 489 differentially expressed genes in P1 relative to all
the processes annotated in the Kyoto Encyclopedia of Genes and
Blood Transcriptional Signature in Autism
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brief, the neurotrophin signaling pathway (KEGG pathway
identifier: hsa04722) was the most significant (EASE score
P=0.00023, FDR 0.0026) among 22 overrepresented pathways
(EASE score P,0.05, corresponding FDR 0.44). The neurotro-
phin signaling pathway includes neurotrophins and their second
messenger systems such as the MAPK pathway, PI3K pathway,
and PLC pathway, which have been identified by others [40,41] as
important for neural development, learning and memory, and
syndromic ASDs such as tuberous sclerosis and Smith-Lemli-Opitz
syndrome. Interestingly, long-term potentiation and long-term
depression pathways were also significant (EASE score P=0.011,
FDR 0.11, and P=0.042, FDR 0.39 respectively). We grouped the
22 overrepresented pathways according to the number of shared
genes by calculating Cohen’s kappa score. Two enriched clusters
of 15 and 3 pathways were significant (Cohen’s kappa.0.5) with
progesterone-mediated oocyte maturation belonging to both
clusters. Five other pathways—notch signaling pathway, lysosome,
leukocyte transendothelial migration, endocytosis, and MAPK
signaling pathway—were not clustered with the others (Table 4).
Given that multiple pathways were significantly enriched with
the differentially expressed genes, we investigated the heterogene-
ity of perturbation across samples. All the significant genes in the
top 14 pathways, from neurotrophin signaling to the VEGF
pathway (Table 4), were grouped together as Pathway Cluster 1. A
majority of these genes were associated with immune response.
The genes in the long-term potentiation and long-term depression
pathways were grouped as Pathway Cluster 2. In this cluster,
synaptic genes were enriched. When the samples were plotted in a
multidimensional space corresponding to the two pathway clusters
(Fig. 1), four subgroups were distinct. The samples in quadrant I of
Figure 1 were perturbed in both Pathway Cluster 1 and Pathway
Cluster 2, while the majority of samples in quadrant III were not
significantly perturbed for either gene set. Interestingly, a
subgroup of ASD samples was only perturbed for Pathway Cluster
2 (quadrant II in Fig. 1), and some were only significant for
Pathway Cluster 1 (quadrant IV in Fig. 1). We also found 6
significant clusters of Gene Ontology biological process terms
grouped by the same approach as KEGG pathways (Cohen’s
kappa.0.5) from 428 overrepresented terms (Table S3), but the
heterogeneity in these terms was not as clear as in KEGG
pathways.
Prediction of autism using blood gene expression
signatures
To test whether peripheral blood gene expression profiles could
be used as a molecular diagnostic tool for identifying ASD, we
used a repeated leave-group out cross-validation (LGOCV)
Table 2. Quantitative RT-PCR validations of 12 differentially expressed genes.
qRT-PCR Microarray
Gene TaqMan Primer ID Fold change p-value Fold change p-value
CREBZF Hs02742201_s1 1.73 0.000127974 1.60 8.8516E-05
HNRNPA2B1 Hs00955384_m1 1.35 0.00119253 1.53 4.2587E-06
KIDINS220 Hs01057000_m1 2.16 8.44446E-10 1.57 2.674E-05
LBR Hs01032700_m1 2.50 7.55278E-10 1.63 5.85338E-05
MED23 Hs00606608_m1 2.24 1.95917E-09 1.51 0.000259037
RBBP6 Hs00544663_m1 1.98 0.000388767 1.58 0.000156489
SPATA13 Hs01128069_m1 1.61 0.000236786 1.56 6.07308E-05
SULF2 Hs01016476_m1 1.89 5.58742E-08 1.72 7.35118E-06
TMEM30A Hs01092148_m1 3.19 4.27915E-10 1.84 7.26489E-05
ZDHHC17 Hs00604479_m1 3.82 7.3983E-12 1.61 1.22144E-05
ZMAT1 Hs00736844_m1 0.60 0.413889282 1.86 8.81564E-05
ZNF12 Hs00212385_m1 2.35 9.12987E-09 1.54 1.86789E-06
We selected 12 significantly differentially expressed genes that had average fold change greater than 1.5 and mean expression levels greater than 150 in the P1 dataset,
and validated changes using quantitative RT-PCR. A total of 30 ASD and 30 control samples from the P1 population were run in replicates of four on the Biomark real
time PCR system (Fluidigm, CA) using nanoliter reactions and the Taqman system (Applied Biosystems, CA). We were limited to 60 samples because the other 39
samples did not have enough RNA for qRT-PCR. The housekeeping gene used for qRT-PCR normalization was GAPDH (Hs9999905_m1). The values shown are for 30 ASD
and 30 control samples from the P1 population, and fold changes refer to ASD/Control. P-values were calculated using Welch’s t-test. For microarray data, p-values and
fold changes were recalculated using the available samples. Eleven of 12 genes (all except ZMAT1) were successfully validated.
doi:10.1371/journal.pone.0049475.t002
Table 3. Differentially expressed genes in CNV regions previously linked to ASD.
Copy number variation Differentially expressed genes in P1 dataset
Gain ADAM10, AP1G1, CCNL1, CLIP1, DDX55, DOCK8, GRIPAP1, HIPK3, JMJD1C, KLHL2, MAPK8, MTMR10, PCGF3, RNF111,
SACS, SNX27, SPATA13, TAOK3, WDR7, ZNF268, ZZEF1
Loss ANTXR2, ATRN, FRMD4B, HECA, ING5, LIFR, OR10A4, SIN3A, UTRN, VAV3, ZC3H13, ZNF548, ZNF592
Gain and loss AHR, CRKL, DMXL1, KBTBD11, KIAA0947, KIAA1468, MAPK1, TRIO, ZBED4, ZNF516
doi:10.1371/journal.pone.0049475.t003
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(P1) was utilized to determine a classification signature (i.e. a
combination of gene expression measurements) that was used to
classify ASD patients in P1 (compared to controls). We ranked the
489 differentially expressed genes according to their area under
the receiver operating characteristic (ROC) curve (AUC). Next we
excluded those genes with low expression, requiring the minimum
expression level across all samples to be at least 150. A total of 391
differentially expressed genes were then utilized in building the
prediction models, which were subsequently tested against the
samples in our independent validation cohort (P2). The top N
genes (where N ranges from 10 to 390 incremented by 5) were
used to build prediction models using a repeated 5-folds LGOCV
with a partial least squares (PLS) method [42,43], and AUCs were
calculated for each cross-validation instance (see Methods). The
prediction model using the top 55 genes was the most stable from
100-repeated LGOCV, having the smallest coefficient of variation
in AUCs from 100 trials (Fig. S3). The top 55 genes performed
significantly better than the 50-gene model (one sided t test
P=0.00031). We chose the 55-gene prediction model because it
minimized description length—i.e., the number of predictor
genes—while maintaining good prediction performance, and used
it to evaluate the independent dataset, P2. The 55 significant genes
are listed in Table S4. The performance of PLS was comparable to
that of other prediction algorithms (Table S5); thus the classifi-
cation performance was not attributable to a specific prediction
algorithm.
The accuracy of this 55-gene set (hereafter referred to as
ASD55) within P1 was unsurprisingly high since it was the training
set (AUC 0.98, 95% confidence interval (CI), 0.965–1.000), but
ASD55 also had good performance when applied to the P2
validation population (AUC 0.70, 95% CI 0.623–0.773) (Table 5).
When generating a set of genes to classify samples, a tradeoff
between specificity and sensitivity must be considered to achieve
optimal results as shown by the ROC curves in Fig. 2A. To
address whether the ASD55 classifier performed better than
Table 4. Top 22 KEGG pathways enriched for differentially expressed genes in ASD (P1).
KEGG pathways Count
EASE score
P FDR (%) Genes
Pathway Cluster 1
Neurotrophin signaling pathway 13 0.00023 0.26 MAP2K1, PIK3CB, PIK3CD, KIDINS220, MAPK1, YWHAG, MAP3K5,
RPS6KA3, CRKL, MAPK14, SH2B3, MAPK8, CRK
Fc gamma R-mediated phagocytosis 9 0.00303 3.41 MAPK1, PTPRC, DOCK2, CRKL, VAV3, MAP2K1, PIK3CB, PIK3CD, CRK
Renal cell carcinoma 8 0.00307 3.45 MAPK1, CRKL, MAP2K1, PIK3CB, PIK3CD, CREBBP, EGLN1, CRK
Chemokine signaling pathway 12 0.01094 11.82 MAPK1, DOCK2, CRKL, VAV3, ROCK1, MAP2K1, GNAI1, PIK3CB, PREX1,
PIK3CD, CCR2, CRK
Regulation of actin cytoskeleton 14 0.01174 12.62 GNA13, VAV3, MAP2K1, ROCK1, PIK3CB, PIK3CD, SSH2, IQGAP2, ITGB2,
MAPK1, CRKL, ITGAV, PPP1R12A, CRK
mTOR signaling pathway 6 0.01358 14.47 MAPK1, RPS6KA3, PIK3CB, PIK3CD, CAB39, RICTOR
Chronic myeloid leukemia 7 0.01413 15.01 MAPK1, CRKL, CTBP2, MAP2K1, PIK3CB, PIK3CD, CRK
Fc epsilon RI signaling pathway 7 0.02189 22.35 MAPK1, VAV3, MAP2K1, PIK3CB, MAPK14, PIK3CD, MAPK8
B cell receptor signaling pathway 6 0.02773 27.48 MAPK1, VAV3, MAP2K1, PIK3CB, PIK3CD, PPP3CB
T cell receptor signaling pathway 8 0.02797 27.69 MAPK1, PTPRC, VAV3, MAP2K1, PIK3CB, MAPK14, PIK3CD, PPP3CB
Focal adhesion 12 0.02878 28.38 IGF1R, MAPK1, CRKL, VAV3, ROCK1, MAP2K1, PIK3CB, ITGAV, PIK3CD,
PPP1R12A, MAPK8, CRK
ErbB signaling pathway 7 0.02987 29.29 MAPK1, CRKL, MAP2K1, PIK3CB, PIK3CD, MAPK8, CRK
Natural killer cell mediated cytotoxicity 8 0.04051 37.66 IFNAR2, MAPK1, VAV3, MAP2K1, PIK3CB, PIK3CD, PPP3CB, ITGB2
VEGF signaling pathway 6 0.04888 43.6 MAPK1, MAP2K1, PIK3CB, MAPK14, PIK3CD, PPP3CB
Pathway Cluster 1 and 2
Progesterone-mediated oocyte maturation 9 0.00408 4.57 IGF1R, MAPK1, RPS6KA3, MAP2K1, GNAI1, PIK3CB, MAPK14, PIK3CD,
MAPK8
Pathway Cluster 2
Long-term potentiation 7 0.01054 11.4 MAPK1, RPS6KA3, GNAQ, MAP2K1, CREBBP, PPP3CB, PPP1R12A
Long-term depression 6 0.04209 38.82 GNA13, IGF1R, MAPK1, GNAQ, MAP2K1, GNAI1
Not clustered
Notch signaling pathway 6 0.00536 5.96 CTBP2, KAT2B, MAML1, CREBBP, ADAM17, MAML3
Lysosome 9 0.01136 12.24 LAMP1, NPC1, AP1G1, HEXB, GAA, CTSD, PPT1, CLTC, MANBA
Leukocyte transendothelial migration 9 0.0174 18.18 RASSF5, VAV3, ROCK1, GNAI1, PIK3CB, MAPK14, PIK3CD, PECAM1,
ITGB2
Endocytosis 11 0.02135 21.85 EPS15, IGF1R, RNF103, RAB22A, RAB5A, GIT2, SH3KBP1, PDCD6IP,
CLTC, ARAP2, ARAP1
MAPK signaling pathway 14 0.04635 41.86 MAP2K1, NLK, TAOK3, PPM1B, MAP4K4, MAPK1, MAP3K5, RPS6KA3,
CRKL, MAPK14, PPP3CB, MAPK8, CRK, RASA1
doi:10.1371/journal.pone.0049475.t004
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and the performances of these random sets were evaluated by
AUCs. Our ASD55 model outperformed all of the 2,000 trials of
randomly chosen sets of 55 genes (permutation P,0.0005). Since
the majority of our training set (P1) consisted of ASD patients, we
checked if the performance of ASD55 was inflated from such
imbalances by calculating the ‘balanced accuracy’ [44]. The
balanced accuracy is defined as the average of the accuracies
obtained in either class (patients and control), or, equivalently, the
arithmetic mean of specificity and sensitivity. It is equal to the
conventional accuracy if the classifier performs equally well on
both classes, but if the classifier’s accuracy is entirely due to
imbalance in the data the balanced accuracy will drop to random
chance (0.5). The average balanced accuracy of ASD55 within P1
was 0.72, which is higher than random chance (0.5) implying that
ASD55 was not entirely affected by imbalanced data [44]. Our
training set (P1) consisted of males only while the test set (P2) had
both genders. Unsurprisingly, the prediction model built with
males performed better for males in P2. The AUC for male
samples in P2 was 0.73 (95% CI 0.645–0.824) compared to 0.51
(95% CI 0.357–0.672) for female samples. To test the robustness
of ASD55, we trained ASD55 with P2 samples to classify P1
samples, switching our training and validation sets. The perfor-
mance was comparable to the original classification accuracy
where P1 was used as the training set (AUC 0.69, 95% CI 0.583–
0.797, Fig. 2B). All male patients with intellectual disability were
accurately classified in both training and validation datasets while
two female cases were predicted as non-cases.
Overall, the ASD55 predictor genes were enriched with 2
KEGG pathways (TGF-beta signaling pathway and Neurotrophin
signaling pathway) and 8 Gene Ontology biological process terms
(Table S6). It may be worth noting that 29 out of 55 predictor
genes were associated with expression in the brain according to
enrichment analysis using DAVID on UniProt tissue expression
categories (UP_TISSUE, EASE score P=0.071, FDR 53.88).
Also, hierarchical clustering of samples in P1 by the ASD55
predictor genes showed a clear distinction between ASD patients
and controls (Fig. 3).
Figure 1. Heterogeneous subgroups in dysregulated pathways. For immune response and synaptic gene sets, robust Mahalanobis distances
(RDs) were calculated for all P1 samples. The outlier cutoff was set at the 97.5% quantile of the chi-squared distribution for each gene set (dotted
green lines). When all samples were plotted in the 2-dimensional plane of Pathway Cluster 1 (x axis) by RDs in the Pathway Cluster 2 (y axis) (Table 4),
four subgroups of samples were distinct. Both gene sets were perturbed for the samples in quadrant I; however, the samples in quadrants II and IV
were significant for one gene set but not the other. A majority of samples were in quadrant III where no significant perturbation was found. The
marginal density plots show the RD distributions for each gene set. Twenty-three out of 66 ASD samples (34.8%) were outliers for the synaptic gene
set compared to 4 of 33 for controls (12.1%) (Fisher’s exact test P=0.017). For the immune response gene set, outliers were not biased towards case
or control (Fisher’s exact test P=0.36).
doi:10.1371/journal.pone.0049475.g001
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gene expression
In order to ensure that our predictor was robust for ASD
classification, we reviewed the expression data for potential
confounders. Among the demographic and clinical features, age
at time of blood draw significantly influenced gene expression.
Within the ASD group, age at blood collection was correlated
within 382 genes at a significance level of P,0.001 (Spearman’s
rank correlation test, N=66, corresponding FDR 0.018). Six
KEGG pathways were significantly enriched with the 382 age-
correlated genes in the P1 ASD population (Table S7). The carbon
pool by folate pathway (KEGG ID: hsa00670) was the most
significantly enriched with age-correlated genes (EASE score
P=4.6610
27, FDR 5.2610
24). The age-correlated genes in this
pathway were MTHFD1, TYMS, SHMT2, ATIC, DHFR,
MTHFD1L, and GART. The ASD55 genes were not significantly
correlated with age except for CNTRL and UTY, which were
correlated with age in patients but not controls. UTY was one of
the 23 genes that were differentially expressed in both datasets (P1
and P2). In the P1 control group (N=33), 163 genes correlated
significantly with age, but none of the ASD55 genes were among
them.
Several other clinical and developmental characteristics were
also correlated with gene expression changes as summarized in
Table 6. A positive personal history of developmental delay
including a delay in hitting milestones such as sitting, crawling,
walking, and speaking was associated with 12 genes including the
aristaless related homeobox gene (ARX). ARX is a homeodomain
transcription factor that plays crucial roles in cerebral develop-
ment and patterning [45], and is implicated in X-linked
intellectual disability [46]. ARX was not differentially expressed
in the ASD group of P1 (P=0.74); however, it was significantly
down-regulated in the individuals with positive history of
developmental delay (P=0.00037, FDR 0.30).
In the P1 cohort, 9 patients with ASD were diagnosed with
leaning disorders. Sixty-four genes were differentially expressed
with regard to learning disorders (Positive History N=9, Negative
History N=90, P,0.001, corresponding FDR 0.14). The calcium
signaling pathway (KEGG ID: hsa04020) was significant (hyper-
geometric P=0.023, FDR 0.19) due to ADRA1B, CHRM2,
PPP3R1, and P2RX3. Another gene differentially expressed in
patients with learning disorders, Synapsin 2 (SYN2), is a synaptic
vesicle-associated protein that has been implicated in modulation
of neurotransmitter release and in synaptogenesis. A brain gene
expression study showed that SYN2 was down-regulated in the
Figure 2. Performance of the ASD55 prediction model. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the
prediction accuracy. The dotted diagonal line represents random classification accuracy (AUC 0.5). A. The accuracy of ASD55 within P1 was
unsurprisingly high (AUC 0.98, 95% confidence interval (CI), 0.965–1.000, black ROC curve). The ASD55 model was trained with P1 to predict the
diagnosis of each sample in an independently collected dataset P2 (dark blue ROC curve). The performance measured by AUC was 0.70 (95% CI, 0.62–
0.77). ASD55 genes showed similar performance when the training and testing datasets were switched (AUC 0.69, 95% CI 0. 58–0.80, brown ROC
curve). B. P2 male samples were accurately predicted (dark green) while female samples (red) were not (AUC 0.73 and 0.51 respectively) when the
ASD55 model was trained with P1.
doi:10.1371/journal.pone.0049475.g002
Table 5. Prediction performance of ASD55 trained with P1.
Validation Set
AUC (95% Confidence
Intervals) Accuracy (%) Sensitivity (%) Specificity (%)
Positive Predictive
Value (%)
Negative Predictive
Value (%)
P2 0.70 (0.623–0.773) 67.7 69.2 65.9 72.0 62.8
P2 (male) 0.73 (0.645–0.824) 72.7 90.0 43.8 72.7 72.4
P2 (female) 0.51 (0.357–0.672) 63.8 50.0 73.5 57.1 67.6
Abbreviations: ASD55, the genes in a classifier developed on P1 with 55 genes listed in Table S4; AUC, area under the receiver operating characteristic curve.
doi:10.1371/journal.pone.0049475.t005
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expressed genes that were correlated with other clinical conditions
including psychiatric, neurological, gastrointestinal disorders, and
seizure disorder are summarized in Table 6.
Discussion
Prior studies have shown differentially expressed genes and
miRNAs in brain [48–52] and blood [15–23] samples from
patients with ASD. This study further examines gene expression
and demonstrates the capability of blood gene expression profiling
to distinguish ASD patients from controls, with an average
Figure 3. Cluster analysis of the 55 genes used in the prediction model (ASD55). The dendrogram and heatmap on top show hierarchical
clustering (average linkage) of the 99 samples in the training set (P1) and the 55 genes used in our prediction model. The first 2 lines in the graph on
bottom indicate whether each sample is from the patient group or the control group. Finally, the bottom line shows the distribution of Fisher’s linear
discriminant scores (dots) based on ASD55 with moving average (line). The distributions of linear discriminant scores are shown on the right (blue
solid line for controls and black broken line for patients). ASD cases and controls are well separated using linear discriminant analysis on the ASD55
genes.
doi:10.1371/journal.pone.0049475.g003
Blood Transcriptional Signature in Autism
PLOS ONE | www.plosone.org 8 December 2012 | Volume 7 | Issue 12 | e49475accuracy of 72.5% in one population (the P1 cohort) and 72.7% in
an independently collected validation population (the P2 cohort).
The classification performance in this study is encouraging,
particularly as the two groups were heterogeneous and profiled
using two different array-types. The classification of 73% of cases
by expression profiling contrasts with the small percentage of ASD
cases characterized by genetic mutations or structural variations to
date. It also compares favorably to the performance of CMA,
which, while high confidence, accounts for only 7–10% of cases of
ASD. Together, these results suggest that gene expression
signatures, which comprise multiple perturbed pathways, may
serve as signals of genetic change suggestive of ASD in most
patients. In this regard, this work parallels studies in neuropsychi-
atry where investigators have demonstrated that blood expression
signatures are significantly different in schizophrenia [53],
Alzheimer’s disease [54], and bipolar disorder [55].
Although the transcriptomic connection between blood and
brain is not well understood, numerous lines of evidence suggest
that measurements in tissues that are not primarily involved in the
disease process may reveal disease signatures. Several investigators
have demonstrated differential expression of genes in peripheral
white blood cells in disorders of the central nervous system [53–
56]. To this point, Sullivan et al. [57] have established a shared
expression profile between different CNS tissues and the blood
suggesting the use of peripheral blood expression as a surrogate for
the brain. Moreover, individual gene expression variations of
multiple brain regions correlate well with those of blood in non-
human primates [58]. Recently, gene expression profiles of
lymphoblastoid cell lines were shown to distinguish between
different forms of ASD caused by defined genetic lesions (Fragile X
syndrome and chromosome 15q duplication) and normal controls
[22], and small studies of patients phenotypically defined with
ASD have shown differential expression of genes in their
peripheral blood cells [20] and in the function of T cell subsets
[19]. These results are mirrored by proteomic studies of serum,
which suggest systematic differences between patients with ASD
and controls [59]. As such, this evidence suggests that peripheral
blood cells might be used as a surrogate for gene expression in the
developing nervous system. Moreover, Glatt et al. recently
reported results from an on-going longitudinal study of blood
gene expression biomarkers in ASD and typically developing
children [60]. They compared peripheral blood mononuclear cell
gene expression profiles from ASD (37 AD and 23 PDD) with 68
non-cases – 27 samples from typically developing children and 41
samples from children who were initially evaluated as a potential
risk group, but later found to be non-cases. Among the 134
differentially expressed genes found by Glatt et al., 5 genes—
ABHD3, COL4A3BP, MAPK14, PARP8, and ZNF763—were also
differentially expressed in our P1 dataset, and ZNF763 was
significant in the P2 data as well. The overlapping genes were all
up-regulated in our datasets while the same genes were all down-
regulated in Glatt et al. except for ZNF763, which was up-
regulated in our two datasets P1 and P2, and in Glatt et al. It is
possible that the effect of age on blood gene expression contributed
to the gene expression changes being opposite for the common
genes. A longitudinal follow-up study of the cohort of Glatt et al.
would give us more conclusive results regarding the validity of
blood gene expression markers at different age groups.
The biological pathways implicated by the differentially
expressed genes identified in this study are of interest because
some of the gene sets link to synaptic activity-dependent processes
(i.e., long-term potentiation and neurotrophin signaling in Table 4),
for which several ASD mutations have been found [40,41].
Immune/inflammatory pathways were also identified in this
analysis (e.g. chemokine signaling and Fc gamma R-mediated
phagocytosis), which have been implicated in several studies of
children with ASD compared to controls through CNS cytopa-
thology [61], serum and CSF proteomics [59], as well as in
cadaveric expression studies of the CNS [51].
According to OMIM, which covers most reported associations
between diseases and genes [62], 6 of the ASD55 genes (11%) are
known disease related genes. Among these 6 genes, CREBBP and
RPS6KA3 were associated with intellectual disability. Heterozygous
mutation of CREBBP causes Rubinstein-Taybi syndrome [63], of
which the core symptom is intellectual disability (MIM ID#
180849). Coffin-Lowry syndrome (MIM ID# 303600) is caused by
mutations in RPS6KA3 on chromosome Xp22.12, and is charac-
terized by skeletal malformation, growth retardation, cognitive
impairments, hearing deficit, and paroxysmal movement disorders
[64].
There remain several potentially important limitations of this
study. The two data sets were obtained at different times and the
Table 6. Genes significantly correlated with clinical features.
Medical and developmental history
Number of significant
genes (p,0.001) Significant genes
Developmental delay 12 ARX,BMS1P1,C20orf196,CCDC18,IBTK,PNRC1,
RHBDL2,TIGD1,TRIM4,ZNF37A,ZNF415,ZNF536
Learning disorders 68 ADRA1B,AKNAD1,ANKRD18A,ANKRD30A,APP,BOD1L,C20orf166-A,
C6orf195,CA2,CACNG5,CAV2,CEP19,CHRM2,CLDN5,CNTNAP3,
CRYGN,CXCL5,DDX11L2,ENSG00000217702,EPHA10,F13A1,
FAM184B,FMO3,GFOD1,GGTA1P,GIF,GNG11,GSC2,HBEGF,
HGD,HRCT1,IGSF11,IGSF22,ITPRIPL2,IZUMO1,KCNA1
,KRT81,LCE1B,LOC126536,LYZL4,MECOM,MSH4,NME
5,NPY,NR1H4,P2RX3,PACS2,PF4V1,PPFIA2,PPP3R1,RAX2,
RNF17,RPL21P68,SCGN,SCN9A,SHH,SLC16A9,SLCO
2B1,SMCR8,SYN2,TCTN2,TEAD1,TMIE,TRH,TXNRD2,
VGLL3,WRB,ZNF652
Neurological disorders 7 FAM13A,LRRD1,PITX3,SH3PXD2B,SPRR4,SPZ1,TACR2,
Psychiatric disorders 5 CSTT,GPR111,HIP1,MED25,STX19
Gastrointestinal disorders 5 COL7A1,MARK1,PLA2G4C,SETMAR,TTR
Seizure disorders 4 GPR153,GSC2,MGC39545,PITX3
doi:10.1371/journal.pone.0049475.t006
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in part from those in P2. Also, the control population in P2 versus
P1 differed in the clinics from which they were drawn, and the
racial and ethnic backgrounds of the patient and control
populations were not completely matched. This heterogeneity
adds noise to the case vs. control comparison and conversely if the
analysis utilized more homogeneous data sets, we would have
expected improved accuracy. Despite these differences, the
independent set reassuringly demonstrates the accuracy of the
classifier. However, if ASD expression endophenotypes exist, we
did not achieve sufficient sample size to discover them. The
inability to identify subtypes within an autism cohort is not
unusual, as it has also been seen in recent genotyping and copy
number variation studies [27,65]. Also, the data were collected
after diagnosis and not as part of a longitudinal study of
individuals. The application of these predictors to a prospective
cohort would allow us to further assess their validity as a diagnostic
and prognostic tool. Finally, our groups with ASD were compared
to developmentally normal controls and not to individuals with
other neurodevelopmental disorders. Nevertheless, the accuracy
we have obtained in this study is a necessary first step towards a
trial validating a set of predictive biomarkers.
In conclusion, this study of children with ASD describes a gene
expression signature that shows promising accuracy in classifying
children with ASD from controls. The ability of the ASD55
predictor to correctly classify ASD samples compares favorably to
the DNA-based tests currently proposed for ASD diagnosis. The
results presented here raise further questions that bear investiga-
tion but are outside this study’s scope: At what age does this
ASD55 signature manifest? Is it present at birth? Finally, we
expect that larger studies can be used to determine whether
particular characteristics of ASD can be classified or predicted
from a gene expression signature (e.g. seizures and language delay)
and thereby improve individualized treatment in the near future.
Materials and Methods
Blood gene expression profiling
Gene expression profiles of P1 were prepared using Affymetrix
HG-U133 Plus 2.0 (U133p2) and those of P2 were profiled using
Affymetrix Gene 1.0 ST (GeneST) arrays (Affymetrix, CA). Within
the P1 data set, RNAs from 39 ASD and 12 control samples were
isolated directly from whole blood using the RiboPure Blood Kit
(Ambion). For all other blood samples, total RNA was extracted
from 2.5 ml of whole venous blood using the PAXgene Blood
RNA System (PreAnalytix) according to the manufacturer’s
instructions. Quality and quantity of these RNAs was assessed
using the Nanodrop spectrophotometer (Thermo Scientific) and
Bioanalyzer System (Agilent). Fragmented cRNA was hybridized
to the appropriate Affymetrix array and scanned on an Affymetrix
GeneChip scanner 3000. cRNA from both affected and normal
control population groups was prepared in batches consisting of a
randomized assortment of the two comparison groups.
Processing of microarray data
Gene expression levels were calculated using Affymetrix Power
Tools version 1.10 (Affymetrix, CA). We used the Probe Log
Iterative ERror (PLIER) algorithm that includes a probe-level
quantile normalization method for each microarray platform
separately [66]. To match the probeset identifiers from the two
different platforms used in this study, we used the Best Match
subset (http://www.affymetrix.com/Auth/support/downloads/
comparisons/U133PlusVsHuGene_BestMatch.zip) between the
two as described in the Affymetrix technical note [67]. 29,129
out of 54,613 total probesets on U133p2 were best matched to
17,984 unique probesets of the GeneST array, and these matched
probesets were used for the cross-platform prediction analysis. For
the genes represented by more than two U133p2 probesets, we
included the genes for which all probesets changed to the same
direction.
To identify hidden confounders such as batch effect, we
performed surrogate variable analysis (SVA) with null model for
batch effect [68]. For the P1 dataset, SVA found 6 surrogate
variables in residuals after fitting with the primary variable of
interest, i.e., clinical diagnosis. The first surrogate variable
significantly correlated with the year when the microarray
profiling was performed. In the P2 dataset, a batch with 12
samples was grouped separately from the other 172 samples from a
principal component analysis although none of the surrogate
variables was correlated with the 12 outlier samples. We used the
ComBat algorithm [69] to reduce the batch effects in P1 and P2
independently as the two array platforms are different in the
design of probe sequences such that U133p2 array uses both
perfect match (PM) and mismatch (MM) probes while GeneST
array only has PM probes. All statistical analyses were performed
with the ComBat corrected expression data.
Statistical analysis for differentially expressed genes and
enriched pathways
To identify differentially expressed genes in cases compared to
controls, we used Welch’s t-test for two group comparison, and
one-way analysis of variance with Dunnett’s post hoc tests to find
significantly changed genes in AUT, PDDNOS, or ASP compared
to the control group. To identify differentially expressed genes in
the P2 dataset, the significance of diagnosis and gender was
determined by two-way analysis of variance and follow-up Welch’s
t-test for each gender and Dunnett’s post hoc tests for subtypes. We
set the threshold for differential expression at nominal p-
value,0.001. A general linear model was used to evaluate the
significance of diagnosis, gender, age, and the other covariates. We
corrected p-values for multiple comparisons by calculating a false
discovery rate (FDR) [70]. We used Fisher’s exact test for
categorical data. Spearman’s rank correlation coefficients were
calculated to evaluate correlation between continuous phenotypic
variables such as age at blood drawing and the expression level of
each gene. The significance of correlation was determined using
Fisher’s r-to-z transformation. Enriched biological pathways with
predictor genes were found using the DAVID functional
annotation system [71]. For significant KEGG pathways, we
calculated the robust Mahalanobis distance of each individual
from the common centroid of all cases and controls to find outliers
using the minimum covariance determinant estimator [72]. A
quantile of the chi-squared distribution (e.g., the 97.5% quantile)
was used as a cut-off to define outliers, because for multivariate
normally distributed data the Mahalanobis distance values are
approximately chi-squared distributed. These outliers can be
interpreted as biologically distinct subgroups for each pathway. All
statistical analysis was performed using the R statistical program-
ming language [73], and robust multivariate outlier analysis was
performed using the chemometrics R library package [72].
Statistical prediction analysis
We performed prediction analysis in the following sequential
steps; 1) ranking genes for predictor selection, 2) setting up a cross-
validation strategy in the training set, 3) tuning parameters and
building prediction models, and 4) predicting a test set, and
evaluating prediction performances (Fig. S4). First, all genes were
ranked by AUC. We selected the top 10 genes from the ranked list
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method in the P1 dataset using a repeated leave-group out cross-
validation (LGOCV) strategy, then repeated the same procedure
with the top N genes incremented by 5 up to 390. For each
prediction model using the top N genes, all P1 samples (N=99)
were divided to 80% (a train set) and 20% (a test set), keeping the
proportion of ASD cases and controls the same in each set. This
step was repeated 100 times to estimate robust prediction
performance (i.e., outer cross validation). To optimize each
prediction model further, an inner cross-validation approach was
deployed where 80% of the samples served as an inner train set,
and 20% were used as an inner test set. The inner cross-validation
procedure was repeated 100 times to find optimal tuning
parameters for the specific prediction algorithm used. For each
prediction model with the top N genes, a total of 10,000
predictions (i.e., 100 repeated LGOCVs 6100 inner cross-
validations) were made.
For each sample in a test set, the model predicts the probability
of being classified as ASD. Thus, the number of false positives
among positive predictions changes with the threshold. Overall
prediction accuracy was calculated as (the number of true
positives+the number of true negatives)/N, where N was the total
number of samples in a dataset. Sensitivity, specificity, positive
predictive value, and negative predictive value were presented as
standard measures of prediction performance with AUC. The
ROC curve summarizes the result at different thresholds.
To find the best performing prediction model with the
minimum description length, we compared AUCs between
prediction models using the top N genes. The mean AUCs
improved gradually with increasing model complexities. However,
we could identify the most stable prediction model by calculating
the coefficient of variation of AUCs with 100 trials of outer cross
validations. We tested 5 additional prediction methods; Logistic
regression, Naı ¨ve Bayes, k-Nearest Neighbors, Random Forest,
and Support Vector Machine using 55 genes with 5 fold LGOCV
strategy (Table S5). Statistical prediction analysis was performed
using the caret [74] and RWeka [75] R library packages.
Quantitative RT-PCR validation
A total of 12 genes using 30 ASD and 30 control samples from
the P1 population were run in replicates of four on the Biomark
real time PCR system (Fluidigm, CA) using nanoliter reactions and
the Taqman system (Applied Biosystems, CA). We were limited to
60 samples because the other 39 samples did not have enough
RNA for qRT-PCR. Following the Biomark protocol, quantitative
RT-PCR (qRT-PCR) amplifications were carried out in a 9
nanoliter reaction volume containing 26 Universal Master Mix
(Taqman), taqman gene expression assays, and preamplified
cDNA. Pre-amplification reactions were done in a PTC-200
thermal cycler from MJ Research, per Biomark protocol.
Reactions and analysis were performed using a Biomark system.
The cycling program consisted of an initial cycle of 50uC for
2 minutes and a 10 min incubation at 95uC followed by 40 cycles
of 95uC for 15 seconds, 70uC for 5 seconds, and 60uC for
1 minute. Data was normalized to the housekeeping gene GAPDH,
and expressed relative to control. All primers used for the 12 genes
are listed in Table 2.
Supporting Information
Figure S1 Principal component analysis of 285 blood
gene expression profiles. Global gene expression profile of the
Training set (P1) and the Validation set (P2) samples. After
selecting the best-matching probe sets between two Affymetrix
microarray platforms (see Methods), principal component analysis
was performed. We applied the ComBat method to reduce batch
effect for each dataset. All samples from P1 and P2 were projected
to two-dimensional space of the first (PC1) and the second (PC2)
principal components after centering and scaling expression levels
in each dataset. 36.5% of overall variance was explained by PC1
and PC2. We did not find global gene expression difference
between ASD cases and controls.
(TIF)
Figure S2 Selecting the predictor genes using repeated
cross validations. Our prediction model selection procedure
consisted of three nested loops as illustrated in Fig. S3. The outer-
most loop was the selection of the top N genes (from 10 to 395
incremented by 5) from the AUC ranked gene list. The second
loop was a leave-group out cross validation approach, where 80%
of samples were randomly selected as a train set, while maintaining
the proportion of each diagnostic class. This step was repeated 100
times for each list of the top N genes. The inner-most loop was
used to optimize the parameters that were specific to machine
learning methods used for a train set from an outer loop. This
parameter tunings were repeated 100 times by randomly selecting
80% of the train set samples. The prediction performance was
estimated using AUC. We found the mean AUCs improved
gradually when we increased the number of genes to build more
complex prediction models (left); however, the top 55 genes
prediction model performed significantly better than the 50 gene
model (t-test P=0.00031) and also presented the smallest
coefficient of variation from 100 repeated cross validations (right).
(TIF)
Figure S3 Predictor gene selection and model building
procedure.
(TIF)
Figure S4 Overlap between differentially expressed
genes for each diagnostic subgroup (ASP, PDD, AUT)
in P1. Only one gene, PTPRE, was found in common as
significant genes for each diagnostic subgroup vs. control. And 36
genes were common between AUT vs. control (177 significant
genes) and PDDNOS vs. control (56 significant genes).
(TIF)
Table S1 Differentially expressed genes in P1. We used
Welch’s t-test for two groups comparison, and one-way analysis of
variance with Dunnett’s post hoc tests to find significantly changed
genes in autistic disorder (AUT), PDD-NOS (PDDNOS), or
Asperger’s disorder (ASP) compared to control group. We
corrected p values for the multiple comparisons by calculating a
false discovery rate (FDR).
(XLS)
Table S2 Differentially expressed genes in P2. We used
Welch’s t-test for the comparison between ASD cases and controls.
To identify differentially expressed genes in P2 dataset, signifi-
cance of diagnosis (p(Dx)) and gender (p(Gender)) was determined
by two-way analysis of variance (ANOVA) and follow-up Welch’s
t-test for each gender. p(Dx*Gender) denotes the interaction
between diagnosis and gender effects for significance. A total of
469 unique genes were differentially expressed (P,0.001,
corresponding FDR 0.023) as there were transcripts without
official gene symbols (i.e., – in Gene field) and several genes have
multiple Affymetrix IDs.
(XLS)
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process terms enriched for differentially expressed
genes in P1 data set.
(XLS)
Table S4 The predictor genes for final prediction
model. The differentially expressed genes were ranked by
AUC, and top 55 genes were selected to build the final prediction
model. Affymetrix IDs represent the transcript IDs of Gene ST 1.0
array. Welch’s t-tests were used to calculate p-values, and false
discovery rates (FDR) were calculated as described in Storey and
Tibshirani.
(XLS)
Table S5 Prediction performance of ASD55 using
various machine learning algorithms. ASD55 denotes the
genes in a classifier developed on P1 with 55 genes (Table S4).
The average prediction performances from 100-repeated leave-
group out cross validations using the P1 dataset are shown. For
each prediction instance, 20% of ASD cases (N=13) and 20% of
controls (N=7) were randomly selected for a testing set, and the
other 80% of samples served as a training set. This procedure was
repeated 100 times to calculate the average performance of
ASD55 with 6 machine learning algorithms listed below. The
overall performance of PLS was comparable to the other 5
methods. The sensitivities were relatively higher than the
specificities across different methods except for the Naı ¨ve Bayes
classifier. (AUC: Area under the receiver operation characteristics
curve, ACC: Accuracy, SENS: Sensitivity, SPEC: Specificity,
PPV: Positive Predictive Value, NPV: Negative Predictive Value).
(XLS)
Table S6 Functional enrichment of genes in ASD55. The
term categories are presented as defined in DAVID.
(XLS)
Table S7 Pathways enriched with age-correlated genes
in ASD.
(XLS)
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